Literature DB >> 19015328

Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.

Junji Hosokawa-Muto1, Yuji O Kamatari, Hironori K Nakamura, Kazuo Kuwata.   

Abstract

Transmissible spongiform encephalopathies are associated with the conformational conversion of the prion protein from the cellular form (PrP(C)) to the scrapie form. This process could be disrupted by stabilizing the PrP(C) conformation, using a specific ligand identified as a chemical chaperone. To discover such compounds, we employed an in silico screen that was based on the nuclear magnetic resonance structure of PrP(C). In combination, we performed ex vivo screening using the Fukuoka-1 strain-infected neuronal mouse cell line at a compound concentration of 10 microM and surface plasmon resonance. Initially, we selected 590 compounds according to the calculated docked energy and finally discovered 24 efficient antiprion compounds, whose chemical structures are quite diverse. Surface plasmon resonance studies showed that the binding affinities of compounds for PrP(C) roughly correlated with the compounds' antiprion activities, indicating that the identification of chemical chaperones that bind to the PrP(C) structure and stabilize it is one efficient strategy for antiprion drug discovery. However, some compounds possessed antiprion activities with low affinities for PrP(C), indicating a mechanism involving additional modulation factors. We classified the compounds roughly into five categories: (i) binding and effective, (ii) low binding and effective, (iii) binding and not effective, (iv) low binding and not effective, and (v) acceleration. In conclusion, we found a spectrum of compounds, many of which are able to modulate the pathogenic conversion reaction. The appropriate categorization of these diverse compounds would facilitate antiprion drug discovery and help to elucidate the pathogenic conversion mechanism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19015328      PMCID: PMC2630596          DOI: 10.1128/AAC.01112-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation.

Authors:  K Doh-Ura; T Iwaki; B Caughey
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Screening for drug discovery: the leading question.

Authors:  Adam Smith
Journal:  Nature       Date:  2002-07-25       Impact factor: 49.962

3.  A detailed comparison of current docking and scoring methods on systems of pharmaceutical relevance.

Authors:  Emanuele Perola; W Patrick Walters; Paul S Charifson
Journal:  Proteins       Date:  2004-08-01

4.  Successful transmission of three mouse-adapted scrapie strains to murine neuroblastoma cell lines overexpressing wild-type mouse prion protein.

Authors:  N Nishida; D A Harris; D Vilette; H Laude; Y Frobert; J Grassi; D Casanova; O Milhavet; S Lehmann
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

5.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.

Authors:  C Korth; B C May; F E Cohen; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

6.  New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products.

Authors:  David A Kocisko; Gerald S Baron; Richard Rubenstein; Jiancao Chen; Salomon Kuizon; Byron Caughey
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase.

Authors:  Rachel A Powers; Federica Morandi; Brian K Shoichet
Journal:  Structure       Date:  2002-07       Impact factor: 5.006

8.  Evaluation of quinacrine treatment for prion diseases.

Authors:  A Barret; F Tagliavini; G Forloni; C Bate; M Salmona; L Colombo; A De Luigi; L Limido; S Suardi; G Rossi; F Auvré; K T Adjou; N Salès; A Williams; C Lasmézas; J P Deslys
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis.

Authors:  Junichiro Matsuda; Osamu Suzuki; Akihiro Oshima; Yoshie Yamamoto; Akira Noguchi; Kazuhiro Takimoto; Masayuki Itoh; Yuji Matsuzaki; Yosuke Yasuda; Seiichiro Ogawa; Yuko Sakata; Eiji Nanba; Katsumi Higaki; Yoshimi Ogawa; Lika Tominaga; Kousaku Ohno; Hiroyuki Iwasaki; Hiroshi Watanabe; Roscoe O Brady; Yoshiyuki Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-15       Impact factor: 11.205

10.  Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein.

Authors:  Martin Vogtherr; Susanne Grimme; Bettina Elshorst; Doris M Jacobs; Klaus Fiebig; Christian Griesinger; Ralph Zahn
Journal:  J Med Chem       Date:  2003-08-14       Impact factor: 7.446

View more
  20 in total

1.  A Promising Antiprion Trimethoxychalcone Binds to the Globular Domain of the Cellular Prion Protein and Changes Its Cellular Location.

Authors:  N C Ferreira; L M Ascari; A G Hughson; G R Cavalheiro; C F Góes; P N Fernandes; J R Hollister; R A da Conceição; D S Silva; A M T Souza; M L C Barbosa; F A Lara; R A P Martins; B Caughey; Y Cordeiro
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Prion 2016 Poster Abstracts.

Authors: 
Journal:  Prion       Date:  2016       Impact factor: 3.931

3.  Prediction of antiprion activity of therapeutic agents with structure-activity models.

Authors:  Katja Venko; Špela Župerl; Marjana Novič
Journal:  Mol Divers       Date:  2013-09-20       Impact factor: 2.943

4.  Thienoquinolins exert diuresis by strongly inhibiting UT-A urea transporters.

Authors:  Huiwen Ren; Yanhua Wang; Yongning Xing; Jianhua Ran; Ming Liu; Tianluo Lei; Hong Zhou; Runtao Li; Jeff M Sands; Baoxue Yang
Journal:  Am J Physiol Renal Physiol       Date:  2014-10-08

5.  Structurally distinct toxicity inhibitors bind at common loci on β-amyloid fibril.

Authors:  Ben Keshet; Jeffrey J Gray; Theresa A Good
Journal:  Protein Sci       Date:  2010-12       Impact factor: 6.725

Review 6.  The therapeutic potential of chemical chaperones in protein folding diseases.

Authors:  Leonardo Cortez; Valerie Sim
Journal:  Prion       Date:  2014-05-12       Impact factor: 3.931

7.  Poly-L-histidine inhibits prion propagation in a prion-infected cell line.

Authors:  Ryo Honda; Kei-Ichi Yamaguchi; Abdelazim Elsayed Elhelaly; Mitsuhiko Fuji; Kazuo Kuwata
Journal:  Prion       Date:  2018-08-17       Impact factor: 3.931

8.  Establishment of a simple cell-based ELISA for the direct detection of abnormal isoform of prion protein from prion-infected cells without cell lysis and proteinase K treatment.

Authors:  Zhifu Shan; Takeshi Yamasaki; Akio Suzuki; Rie Hasebe; Motohiro Horiuchi
Journal:  Prion       Date:  2016-07-03       Impact factor: 3.931

9.  Neuroprotective function of cellular prion protein in a mouse model of amyotrophic lateral sclerosis.

Authors:  Petra Steinacker; Andreas Hawlik; Stefan Lehnert; Olaf Jahn; Stephen Meier; Evamaria Görz; Kerstin E Braunstein; Marija Krzovska; Birgit Schwalenstöcker; Sarah Jesse; Christian Pröpper; Tobias Böckers; Albert Ludolph; Markus Otto
Journal:  Am J Pathol       Date:  2010-01-14       Impact factor: 4.307

10.  Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones.

Authors:  Yuji O Kamatari; Yosuke Hayano; Kei-ichi Yamaguchi; Junji Hosokawa-Muto; Kazuo Kuwata
Journal:  Protein Sci       Date:  2012-11-19       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.